Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Ferrer

Gastroenterology Miami, FL Medical Doctor

NPI 1013975911 CMS profile 318485

8950 N Kendall Dr, Suite 306, Miami, FL 33176

Open in the dashboard

General payments

$11,917

770 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Ferrer of Miami, FL is reported in the CMS Open Payments database as having received $11,917 across 770 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,215 120
2024 General $1,882 102
2023 General $2,369 148
2022 General $2,344 158
2021 General $1,818 143
2020 General $371 24
2019 General $917 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Ferrer
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jose Ferrer were reported at $2,215. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jose Ferrer Gastroenterology median Middle half National median
2019 $917 $417 $126–$1,100 $163
2020 $371 $224 $74–$624 $114
2021 $1,818 $352 $106–$1,054 $132
2022 $2,344 $448 $129–$1,270 $149
2023 $2,369 $533 $150–$1,390 $160
2024 $1,882 $605 $160–$1,606 $164
2025 $2,215 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,824 152 payments
  2. AbbVie, Inc. $1,623 106 payments
  3. QOL Medical, LLC $1,212 90 payments
  4. Janssen Biotech, Inc. $1,155 66 payments
  5. Genzyme Corporation $861 33 payments
  6. Celgene Corporation $578 44 payments
  7. Ardelyx, Inc. $508 35 payments
  8. Regeneron Healthcare Solutions, Inc. $387 16 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $378 18 payments
  10. RedHill Biopharma Inc. $369 37 payments
  11. Other $3,022 173 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,680 766 payments
  2. Education $236 4 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,630 135 payments
  2. DUPIXENT $861 33 payments
  3. STELARA $790 49 payments
  4. RINVOQ $639 36 payments
  5. ZEPOSIA $571 42 payments
  6. Sucraid $555 46 payments
  7. IBSRELA $508 35 payments
  8. LINZESS $489 36 payments
  9. HUMIRA $450 27 payments
  10. CREON $439 33 payments
  11. Other $6,990 458 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,258

Median for Gastroenterology: 569

Drug cost

$467,552

Median for Gastroenterology: $104,976

Branded share of claims

30.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 38 $124,471
Linzess Linaclotide Brand 114 $101,406
Creon Lipase/Protease/Amylase Brand 21 $97,633
Xifaxan Rifaximin Brand 29 $88,872
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 113 $19,680
Mesalamine Generic 42 $17,992
Famotidine Generic 200 $3,870
Pantoprazole Sodium Generic 303 $2,212
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 15 $1,875
Dicyclomine Hcl Generic 92 $1,704

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$38,308

Medicare's payments for the services billed

Medicare patients

209

Average age 74

Services billed

331

130 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 41%
Ischemic heart disease 41%
Depression 34%
Chronic kidney disease 27%
Osteoporosis 23%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $198
  • Regeneron Healthcare Solutions, Inc. $109
$307 — —
Sucraid
  • QOL Medical, LLC $240
$240 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $151
$151 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $105
  • AbbVie, Inc. $38
$143 114 —
STELARA
  • Janssen Biotech, Inc. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

770 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record